Liposomal Doxorubicin and Gemcitabine in Treating Women With Metastatic Breast Cancer

Pharmatech, Inc.

Status and phase: Unknown; Phase 2

Conditions: Breast Cancer

Treatments: Drug: gemcitabine hydrochloride; Drug: pegylated liposomal doxorubicin hydrochloride

Study type: Interventional

Funder types: Industry

Identifiers

NCT00027989

PHARMATECH-20002183

PHARMATECH-P01-00002008

CDR0000069104

ORTHO-PHARMATECH-P01-000020008

Details and patient eligibility

About

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of combining liposomal doxorubicin with gemcitabine in treating women who have metastatic breast cancer.

Full description

OBJECTIVES:

• Determine the objective response rate in women with metastatic breast cancer treated with doxorubicin HCl liposome and gemcitabine.
• Determine the duration of response, time to disease progression, and duration of survival of patients treated with this regimen.
• Determine the quality of life of patients treated with this regimen.
• Determine the quantitative toxicity of this regimen, in terms of incidence, type, and severity, in these patients.

OUTLINE: This is a multicenter study.

Patients receive doxorubicin HCl liposome IV over 1 hour on day 1 and gemcitabine IV over 30 minutes on days 1 and 8. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) receive 2 courses beyond documentation of CR.

Quality of life is assessed at baseline, on day 1 of each course, and then at the end of study.

Patients are followed at 4 weeks and then every 3 months for 5 years.

PROJECTED ACCRUAL: A total of 75 patients will be accrued for this study.

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

DISEASE CHARACTERISTICS:

• Histologically or cytologically confirmed metastatic breast cancer

• Measurable disease

• Hormone receptor status:

  • Not specified

PATIENT CHARACTERISTICS:

Age:

• 18 and over

Sex:

• Female

Menopausal status:

• Not specified

Performance status:

• Karnofsky 60-100%

Life expectancy:

• At least 3 months

Hematopoietic:

• Platelet count at least 100,000/mm^3
• Hemoglobin at least 9 g/dL
• Absolute neutrophil count at least 1,500/mm^3
• No impaired bone marrow function

Hepatic:

• Bilirubin no greater than 2 mg/dL
• AST and ALT no greater than 2 times upper limit of normal (ULN)
• Alkaline phosphatase no greater than 2 times ULN (unless attributed to tumor)
• No impaired hepatic function

Renal:

• Creatinine no greater than 2.5 mg/dL OR
• Creatinine clearance at least 60 mL/min
• No impaired renal function

Cardiovascular:

• No prior cardiac disease within the past 5 years OR
• LVEF at least 50%

Other:

• No prior uncontrolled seizures
• No uncontrolled systemic infection
• No anthracycline resistance
• No other malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• No prior trastuzumab (Herceptin)

Chemotherapy:

• Prior adjuvant therapy with anthracycline of no more than 320 mg/m^2 allowed

Endocrine therapy:

• Not specified

Radiotherapy:

• No prior radiotherapy to more than 1/3 of hematopoietic sites

Surgery:

• Not specified

Other:

• At least 30 days since prior investigational medications and recovered
• No more than 1 prior treatment regimen for metastatic disease